Pharma giant AstraZeneca (LON:AZN) has swooped in for a rival’s executive.
Dr Sean Bohen - joining on September 15 from Genentech, a Roche subsidiary - will be in charge of small molecules and biologics investigational medicines portfolio, as well as patient safety, the FTSE 100 drug company said.
He will take up the position of executive vice president of global medicines development and chief medical officer.
Pascal Soriot, chief executive, said: “His impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients.”
Bohen was most recently in charge of Genentech’s preclinical and clinical development programmes, including oncology, respiratory and autoimmune diseases Astra said, adding that he played “a key role in the growth and progress of the Genentech/Roche portfolio.”
AstraZeneca was one of the better performers on the FTSE 100 but still was still 1.3% lower to 4,002p.